

COVID-19 JUNE-JULY-AUGUST 2022 WALLINGFORD HEALTH DEPARTMENT

September 4th, 2022

Daniela Babcock

Epidemiologist




COVID-19 CASES IN WALLINGFORD FROM JUNE TO AUGUST, 2022

On June, 2022, the Town of Wallingford had 302 covid-19 cases (confirmed and probable) reported to the Connecticut Department of Health (CT DPH), with a case rate of 22.7 per 100,000 residents.

On July, 2022, 395 covid-19 cases, with a case rate of 28.7 per 100,000 residents.

And on August, 2022, 341 covid-19 cases, with a case rate of 24.8 per 100,000 residents.

Resulting in a total of 11,633 covid-19 cases reported in the Town of Wallingford as of August 31st, 2022, since the beginning of the Covid-19 pandemic.



Wallingford Town - Population 44,326								
Date data were	Cumulative Covid-19 case	Cumulative count of all NAAT tests and positive	Cumulative count of all positive NAAT tests	Cumulative count of all NAAT tests				
reported	count	Antigen tests						
6/16/2022	10,660	232,481	11,472	206,395				
6/30/2022	10,832	234,078	11,644	207,962				
15 days	172	1,597	172	1,567				
7/1/2022	10,892	234,663	11,712	208,540				
7/31/2022	11,287	238,006	12,160	211,805				
31 days	395	3,343	448	3,265				
8/1/2022	11,292	238,111	12,168	211,911				
8/31/2022	11,633	240,794	12,609	214,558				
31 days	341	2,683	441	2,647				
6/16/2022	10,660	232,481	11,472	206,395				
8/31/2022	11,633	240,794	12,609	214,558				
77 days	973	8,313	1,137	8,163				




COVID-19 DEATHS IN WALLINGFORD FROM JUNE TO AUGUST, 2022

On June, 2022, there was 1 fatality recorded in the Connecticut Surveillance System in Wallingford due to covid-19.

On July, 2022, there were 2 fatalities.

And on August, 2022, there were also 2 fatalities in the Town of Wallingford.

Resulting in a total of 222 cumulative deaths in the Town of Wallingford due to covid-19 as of August 31st, 2022, since the beginning of the Covid-19 pandemic.






COVID-19 VACCINE IN WALLINGFORD FROM JUNE TO AUGUST, 2022

On June, in Wallingford, 283 residents initiated their covid-19 vaccine primary series. On July, 102 residents, and on August, 114 residents.

On June, 184 residents completed their primary series of the covid-19 vaccine (fully vaccinated). On July, 56 residents, and August, 96 residents.

On June, 107 residents received an additional booster dose (up to date). On July, 179 residents, and August, 237 residents.


*June, July and August of 2022.







COVID-19 VACCINE IN WALLINGFORD FROM JUNE TO AUGUST, 2022

In the three graphs below is possible to observe the increase in the Covid-19 initiated vaccination, fully vaccinated and additional dose percentage per age from June, 2022 to August, 2022 in the Town of Wallingford.










COVID-19 VACCINE IN WALLINGFORD FROM JUNE TO AUGUST, 2022

As of August 31st, 2022, from 44,326
Wallingford residents, 37,075 residents
initiated their Covid-19 vaccination primary
series (83.64%). From it 34,838 are
considered fully vaccinated (78.59%) and
22,626 have received an additional dose
(51.04%).






COVID-19 HOSPITALIZATIONS AT WALLINGFORD HOSPITALS FROM JUNE TO AUGUST, 2022

The Masonicare Health Center, a short-term rehabilitation center, had 62 adult patients hospitalized with covid-19, on June, 2022. Then 189 adult patients on July, 2022, and 0 adult patients on August, 2022.

The Gaylord Hospital, a long-term hospital, had 26 adult patients hospitalized with covid-19, on June, 2022. Then 14 adult patients on July, 2022, and 16 adult patients on August, 2022.

Both locations had no adult patients hospitalized in the ICU, and no pediatric patients hospitalized during the three month period.






COVID-19 VARIANTS IN WALLINGFORD

Three hundred and eleven covid-19 samples from Wallingford residents were analyzed between June and August 2022 by different laboratories. Among the 311 residents, 166 were females and 130 males. The ages can be seeing on the table on the right.

From the 311 samples, 207 were omicron (66.56%), 68 delta (21.86%), 23 alpha (7.40%), and 13 other variants (Iota, Epsilon and Original variants) (4.18%).

Ages	Number of Resident ▼		
0 to 9	20		
10 to 19	19		
20 to 29	30		
30 to 39	52		
40 to 49	46		
50 to 59	60		
60 to 69	45		
70 to 79	23		
80 to 89	10		
90+	6		
Total	311		




Source: CTEDSS




COMMUNITY LEVEL NEW HAVEN COUNTY


From June, 2022 until August, 2022, the community level of New Haven County, most of the time, was at the medium level, with the exception of the week of July 28th, 2022, when the community level was considered high.



New COVID-19 admissions per 100,000 population (7-day total)



Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average)



Community Level of New Haven County							
Date of data release	Percent of staffed inpatient beds occupied by COVID-19 patients (7-day average)	New COVID-19 admissions per 100,000 population (7-day total)	New COVID-19 cases per 100,000 population (7-day total)	COVID-19 community level [Low, Medium, High]			
6/2/22	4.6%	11.8	161.33	Medium			
6/9/22	4.1%	11.9	112.31	Medium			
6/16/22	3.4%	11	126.23	Medium			
6/23/22	3.5%	11.9	99.79	Medium			
6/30/22	3.5%	11	136.53	Medium			
7/7/22	3.9%	12.4	103.89	Medium			
7/14/22	4.6%	14.6	169.52	Medium			
7/21/22	4.4%	13.9	28.08	Medium			
7/28/22	4.2%	12.1	225.68	High			
8/4/22	4.8%	15.7	182.86	Medium			
8/11/22	5.1%	14.7	195.73	Medium			
8/18/22	4.2%	12.4	148.23	Medium			
8/25/22	5.0%	16.3	135.36	Medium			
9/1/22	4.5%	11.7	118.75	Medium			



UPCOMING CLINICS



We will continue to offer vaccination to homebound individuals as needed.



HHS TO SUSPEND ORDERS OF FREE AT-HOME COVID-19 TESTS

The U.S. Department of Health and Human Resources will suspend ordering of free at-home COVID-19 tests after **Friday**, **September 2**, due to a lack of additional funding to replenish the nation's stockpile of tests.



FDA APPROVAL

- As of July 13th 2022, FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine as primary series for individuals 18 years and older.
- As of August 31, the U.S. Food and Drug Administration (FDA) <u>amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 Vaccines</u> to authorize bivalent formulations of the vaccines for use as a single-booster dose at least two months following primary or booster vaccination. The Moderna COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 18 years of age and older. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent, is authorized for use as a single booster dose in individuals 12 years of age and older.